Kara Hesna, Chazal Nathalie, Bouaziz Serge
Cibles Therapeutiques et Conception de Medicaments (CiTCoM), CNRS UMR8038, Faculte des Sciences Pharmaceutiques et Biologiques, Universite Paris Descartes, Paris, France.
Institut de Recherche en Infectiologie de Montpellier (IRIM), CNRS UMR9004, Universite de Montpellier, Montpellier, France.
Curr HIV Res. 2019;17(3):148-160. doi: 10.2174/1570162X17666190821154331.
Uracil-DNA glycosylase-2 (UNG2) is a DNA repair protein that removes uracil from single and double-stranded DNA through a basic excision repair process. UNG2 is packaged into new virions by interaction with integrase (IN) and is needed during the early stages of the replication cycle. UNG2 appears to play both a positive and negative role during HIV-1 replication; UNG2 improves the fidelity of reverse transcription but the nuclear isoform of UNG2 participates in the degradation of cDNA and the persistence of the cellular genome by repairing its uracil mismatches. In addition, UNG2 is neutralized by Vpr, which redirects it to the proteasome for degradation, suggesting that UNG2 may be a new cellular restriction factor. So far, we have not understood why HIV-1 imports UNG2 via its IN and why it causes degradation of endogenous UNG2 by redirecting it to the proteasome via Vpr. In this review, we propose to discuss the ambiguous role of UNG2 during the HIV-1 replication cycle.
尿嘧啶-DNA糖基化酶2(UNG2)是一种DNA修复蛋白,它通过碱基切除修复过程从单链和双链DNA中去除尿嘧啶。UNG2通过与整合酶(IN)相互作用被包装进新的病毒颗粒中,并且在复制周期的早期阶段是必需的。UNG2在HIV-1复制过程中似乎发挥着正负两方面的作用;UNG2提高了逆转录的保真度,但UNG2的核异构体通过修复其尿嘧啶错配参与cDNA的降解和细胞基因组的持久性。此外,UNG2被Vpr中和,Vpr将其重定向到蛋白酶体进行降解,这表明UNG2可能是一种新的细胞限制因子。到目前为止,我们还不明白为什么HIV-1通过其整合酶导入UNG2,以及为什么它通过Vpr将内源性UNG2重定向到蛋白酶体从而导致其降解。在这篇综述中,我们提议讨论UNG2在HIV-1复制周期中的模糊作用。